

Special Issue

Nanoparticles in Cancer Immunotherapy Application

Message from the Guest Editors

The 2018 Nobel Prize recognized immune checkpoint blockade, which has defined modern cancer immunotherapy, yet variable response, toxicity, and an immunosuppressive tumor microenvironment remain major hurdles. In 2025, the Prize honored discoveries of regulatory T cells and peripheral immune tolerance, spotlighting precise control of immune suppression as a complementary path to refine cancer treatment. Emerging nanoparticle platforms now help bridge these fronts by improving delivery to tumors, inducing immunogenic cell death, enabling radiosensitization, and selectively modulating T-cells. This Special Issue will focus on the design, development, and application of nanoparticles in cancer immunotherapy, highlighting their role in advancing precision medicine and overcoming current therapeutic challenges. We invite researchers and clinicians to submit original research and reviews that explore how nanoparticles are revolutionizing cancer immunotherapy, contributing to improved therapeutic outcomes and new treatment paradigms.

Guest Editors

Prof. Dr. Yongjun Wang

Wuya College of Innovation, Shenyang Pharmaceutical University,
Shenyang 110016, China

Dr. Shuyue Zhan

Department of Chemistry, University of Georgia, Athens, GA 30602,
USA

Deadline for manuscript submissions

31 December 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



mdpi.com/si/259267

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2026).